Back to top
more

G1 Therapeutics (GTHX)

(Delayed Data from NSDQ)

$2.78 USD

2.78
638,099

-0.21 (-7.02%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $2.79 +0.01 (0.36%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GTHX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

G1 Therapeutics [GTHX]

Reports for Purchase

Showing records 301 - 320 ( 353 total )

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 301

04/05/2019

Industry Report

Pages: 23

Biotechnology - AACR Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 302

03/29/2019

Industry Report

Pages: 10

HEALTHCARE: The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 303

03/07/2019

Daily Note

Pages: 7

G1 Analyst Investor Day: Commercial - Regulatory Strategies Emerging for Trila

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 304

03/07/2019

Company Report

Pages: 8

Highlights From Investor Conference: G1 Provides Program Updates; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 305

03/01/2019

Daily Note

Pages: 15

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 306

03/01/2019

Company Report

Pages: 8

G1 Therapeutics Reports 4Q18 Results and Trilaciclib Progress; PT to $72 from $75

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 307

03/01/2019

Company Report

Pages: 7

Whither Trila and Regulators?

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 308

02/08/2019

Daily Note

Pages: 8

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 309

01/18/2019

Industry Report

Pages: 9

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 310

01/14/2019

Industry Report

Pages: 9

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 311

12/20/2018

Company Report

Pages: 7

G1 Therapeutics Again Reports Positive Topline Phase 2 Trilaciclib Myelopreservation Data in SCLC

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 312

12/20/2018

Daily Note

Pages: 6

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 313

12/20/2018

Daily Note

Pages: 5

4/4: G1 Looking to Dance With Regulators in H1:19

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 314

12/05/2018

Daily Note

Pages: 5

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 315

12/05/2018

Company Report

Pages: 8

Trilaciclib Improves PFS in TNBC

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 316

12/04/2018

Daily Note

Pages: 4

Encouraging Trilaciclib Phase 2 Data in mTNBC at San Antonio Breast Meeting

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 317

11/27/2018

Company Report

Pages: 6

G1 Therapeutics Announces Positive Phase 2 Trilaciclib Myelopreservation Data in First-Line SCLC Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 318

11/27/2018

Company Report

Pages: 6

Trila Triple Combo Data Positive, Looking Forward to TNBC Data at SABCS

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 319

11/12/2018

Daily Note

Pages: 3

G1 Therapeutics to Present Phase 2 Trilaciclib Data at San Antonio Breast Meeting

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 320

11/08/2018

Company Report

Pages: 8

3Q Financials; Data-Rich Q4 to Set up 2019 Regulatory Guidance

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party